ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
LEUVEN, Belgium, December 11 /PRNewswire/ --
- TB-402 Shows Clear Promise as a Stable Long-acting Anticoagulant for the Prevention of Thromboembolic Disorders.
ThromboGenics NV (Euronext Brussels:…